Center-Authored Papers

Filters: Author is Gore, John L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter BH, Klotz L et al..  2014.  The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Soci. Archives of pathology & laboratory medicine. Abstract
C
Calvert JK, Holt SK, Mossanen M, James AC, Wright JL, Porter MP, Gore JL.  2014.  Use and Outcomes of Extended Antibiotic Prophylaxis in Urologic Cancer Surgery.. The Journal of urology. Abstract
D
Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL et al..  2015.  Active surveillance for prostate cancer: the role of the pathologist.. Pathology. 47(1):1-3.
F
Figler B, Gore JL, Holt SK, Voelzke B, Wessells H.  2014.  High Regional Variation in Urethroplasty Utilization in the United States.. The Journal of urology. Abstract
Flum DR, Alfonso-Cristancho R, Devine EB, Devlin A, Farrokhi E, Tarczy-Hornoch P, Kessler L, Lavallee D, Patrick DL, Gore JL et al..  2014.  Implementation of a "real-world" learning health care system: Washington state's Comparative Effectiveness Research Translation Network (CERTAIN).. Surgery. 155(5):860-6. Abstract
G
Gore JL, du Plessis M, Santiago-Jiménez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M et al..  2017.  Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.. Cancer. Abstract
Gulati R, Gore JL, Etzioni R.  2013.  Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms.. Annals of internal medicine. 158(3):145-53. Abstract
Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR.  2014.  Expected population impacts of discontinued prostate-specific antigen screening.. Cancer. Abstract
Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R.  2011.  Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.. Journal of clinical epidemiology. 64(12):1412-7. Abstract
Gulati R, Inoue LYT, Gore JL, Katcher J, Etzioni R.  2014.  Individualized estimates of overdiagnosis in screen-detected prostate cancer.. Journal of the National Cancer Institute. 106(2):djt367. Abstract
H
Hartzler AL, Izard JP, Dalkin BL, Mikles SP, Gore JL.  2015.  Design and feasibility of integrating personalized PRO dashboards into prostate cancer care.. Journal of the American Medical Informatics Association : JAMIA. Abstract
Hsi RS, Holt SK, Gore JL, Harper JD.  2014.  Trends in Followup Imaging after Adult Pyeloplasty.. The Journal of urology. Abstract
I
Izard JP, Gore JL, Mostaghel EA, Wright JL, Yu EY.  2015.  Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial Carcinoma.. Clinical genitourinary cancer. Abstract
J
James AC, Holt SK, Wright JL, Porter MP, Gore JL.  2014.  Burden and timing of venothrombolic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer.. Urologic oncology. Abstract
James AC, Lee FC, Izard JP, Harris WP, Cheng HH, Zhao S, Gore JL, Lin DW, Porter MP, Yu EY et al..  2014.  Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer.. Clinical genitourinary cancer. Abstract
L
Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter M et al..  2013.  Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.. Advances in urology. 2013:317190. Abstract
M
Macleod LC, Tykodi SS, Holt SK, Wright JL, Lin DW, Tretiakova MS, True LD, Gore JL.  2015.  Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.. Urology. Abstract
Macleod LC, Rajanahally S, Nayak JG, Parent BA, Ramos JD, Schade GR, Holt SK, Dash A, Gore JL, Lin DW.  2016.  Characterizing the Morbidity of Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients.. Urology. Abstract
Macleod LC, Dai JC, Holt SK, Bassett JC, Wright JL, Gore JL.  2015.  Underuse and underreporting of smoking cessation for smokers with a new urologic cancer diagnosis.. Urologic oncology. Abstract
Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, White E.  2013.  Risk Factors for Renal Cell Carcinoma in the Vitamin and Lifestyle (VITAL) Study.. The Journal of urology. 190(5):1657-61. Abstract
Mossanen M, Calvert JK, Wright JL, True LD, Lin DW, Gore JL.  2014.  Readability of urologic pathology reports: The need for patient-centered approaches.. Urologic oncology. Abstract
Mossanen M, Macleod LC, Chu A, Wright JL, Dalkin B, Lin DW, True L, Gore JL.  2016.  Comparative effectiveness of a patient centered pathology report for bladder cancer care.. The Journal of urology. Abstract
Mossanen M, Izard J, Wright JL, Harper JD, Porter MP, Daratha KB, Holt SK, Gore JL.  2014.  Identification of underserved areas for urologic cancer care.. Cancer. Abstract
Mossanen M, Lee F, Cheng H, Harris W, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL et al..  2013.  Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder.. Clinical genitourinary cancer. Abstract
Mossanen M, Holt S, Gore JL, Lin DW, Wright JL.  2016.  15 Years of penile cancer management in the United States: An analysis of the use of partial penectomy for localized disease and chemotherapy in the metastatic setting.. Urologic oncology. Abstract